FPS
RGNX icon

Fieldpoint Private Securities’s Regenxbio RGNX Stock Holding History

Fieldpoint Private Securities’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15
Closed -$1K – 1627
2020
Q4 		$1K Buy
+15
New +$524 ﹤0.01% 1446

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fieldpoint Private Securities's RGNX Position: Q1 2021 in Review

Fieldpoint Private Securities sold out of Regenxbio (RGNX) in Q1 2021, closing a stake of 15 shares — an estimated $1K sold.

Fieldpoint Private Securities first reported a position in RGNX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 184 funds tracked by Wall St. Rank hold RGNX as of Q1 2021.

  • Fieldpoint Private Securities reported no remaining Regenxbio position as of Q1 2021 after selling out during the quarter.
  • Fieldpoint Private Securities sold 15 Regenxbio shares in Q1 2021, an estimated $1K.
  • Fieldpoint Private Securities first reported a position in Regenxbio in Q4 2020 and held it in 1 quarter.
  • Fieldpoint Private Securities's Regenxbio position peaked at $1K in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Regenxbio as of Q1 2021.

Based on Fieldpoint Private Securities's 13F filing for Q1 2021, filed 23 Apr 2021.